Previous studies revealed that targeting the HIF-1α/PD-L1 pathway with PD-L1 antibodies combined with the HIF-1α inhibitor PX-478 improved the efficacy of anti-PD-1/PD-L1 for glioma [10]. Here, HIF1A is linked to central nervous system cancer.